AZD2171
information and resources from the National Cancer Institute
NCI Thesaurus | AZD2171
An indole ether quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, AZD2171 binds to and inhibits all three vascular endothelial growth factor receptor (VEGF-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. NCI Thesaurus | AZD2171
An indole ether quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, AZD2171 binds to and inhibits all three vascular endothelial growth factor receptor (VEGF-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.
|
|
|
|
news articles
New Study of VEGF Signalling Inhibitor AZD2171 Used in the First ... Nov 23, 2005
PR Newswire UK (press release), ...today the start of recruitment into a pivotal Phase II/III study of the novel Vascular Endothelial Growth Factor (VEGF) signalling inhibitor, AZD2171, in non ...
AstraZeneca AZD2171 Update "Well-Flagged" Nov 23, 2005
New Ratings Traders cite the announcement of AZD2171 moving into phase 3. "This is completely in line...it was flagged as end-'05 in July," he notes. ...
AZD2171 Well Tolerated in Patients with Advanced Prostate Cancer ... Nov 18, 2005
DG News PHILADELPHIA, PA -- November 18, 2005 -- Early data on the investigational agent, AZD2171, show the drug has broad-spectrum antitumor activity in a range of ...
AstraZeneca starts lung cancer drug study Nov 23, 2005
Life Style Extra, Drug goliath AstraZeneca posted gains today after it said it had started recruiting patients into a pivotal Phase II/III study of lung cancer drug AZD2171. ...
UPDATE 1-Astra starts key study for new lung cancer drug Nov 23, 2005
Reuters Quote, Profile, Research) has started recruiting patients for a pivotal Phase II/III clinical study of its experimental lung cancer drug AZD2171, Europe's third ...
AstraZeneca helps FTSE to new high Nov 23, 2005
Guardian Unlimited, ...treatment for lung cancer. The drug, known as AZD2171, works by inhibiting the supply of blood to tumour cells. Investors hope the ...
FTSE 100 movers: Tesco up on US expansion rumour Nov 23, 2005
ShareCast, AstraZeneca moved up as it said it has started recruiting patients for a clinical study of its experimental lung cancer drug AZD2171.
Stockholm shares flat midmorning in quiet trade, Volvo dips on ... Nov 24, 2005
Forbes ...was helping the index, up 0.27 pct at 370.50, following news that the company has initiated a phase II/III study of its experimental lung cancer drug AZD2171. ...
(PRN) - Pharmaceutical and Biotechnology Companies Adopt ... Nov 23, 2005
Bolsamania.com, ...[+]. (PRN) - New Study of VEGF Signalling Inhibitor AZD2171 Used in the First-Line Setting for Patients With Advanced NSCLC ... [+. ...
Astrazeneca Bolstered By Pfizer Win Nov 23, 2005
New Ratings He doesn't feel Astrazeneca's announcement of AZD2171 moving to phase 3, also cited as a reason for the share price rally, is offering significant support. ...
New Study of VEGF Signalling Inhibitor AZD2171 Used in the First ... Nov 23, 2005
PR Newswire UK (press release), ...today the start of recruitment into a pivotal Phase II/III study of the novel Vascular Endothelial Growth Factor (VEGF) signalling inhibitor, AZD2171, in non ...
AstraZeneca AZD2171 Update "Well-Flagged" Nov 23, 2005
New Ratings Traders cite the announcement of AZD2171 moving into phase 3. "This is completely in line...it was flagged as end-'05 in July," he notes. ...
AZD2171 Well Tolerated in Patients with Advanced Prostate Cancer ... Nov 18, 2005
DG News PHILADELPHIA, PA -- November 18, 2005 -- Early data on the investigational agent, AZD2171, show the drug has broad-spectrum antitumor activity in a range of ...
AstraZeneca starts lung cancer drug study Nov 23, 2005
Life Style Extra, Drug goliath AstraZeneca posted gains today after it said it had started recruiting patients into a pivotal Phase II/III study of lung cancer drug AZD2171. ...
UPDATE 1-Astra starts key study for new lung cancer drug Nov 23, 2005
Reuters Quote, Profile, Research) has started recruiting patients for a pivotal Phase II/III clinical study of its experimental lung cancer drug AZD2171, Europe's third ...
AstraZeneca helps FTSE to new high Nov 23, 2005
Guardian Unlimited, ...treatment for lung cancer. The drug, known as AZD2171, works by inhibiting the supply of blood to tumour cells. Investors hope the ...
FTSE 100 movers: Tesco up on US expansion rumour Nov 23, 2005
ShareCast, AstraZeneca moved up as it said it has started recruiting patients for a clinical study of its experimental lung cancer drug AZD2171.
Stockholm shares flat midmorning in quiet trade, Volvo dips on ... Nov 24, 2005
Forbes ...was helping the index, up 0.27 pct at 370.50, following news that the company has initiated a phase II/III study of its experimental lung cancer drug AZD2171. ...
(PRN) - Pharmaceutical and Biotechnology Companies Adopt ... Nov 23, 2005
Bolsamania.com, ...[+]. (PRN) - New Study of VEGF Signalling Inhibitor AZD2171 Used in the First-Line Setting for Patients With Advanced NSCLC ... [+. ...
Astrazeneca Bolstered By Pfizer Win Nov 23, 2005
New Ratings He doesn't feel Astrazeneca's announcement of AZD2171 moving to phase 3, also cited as a reason for the share price rally, is offering significant support. ...
|
|
